Elite Capital Markets and M&A Counsel

Crone is an international law firm providing sophisticated legal counsel to public and private companies and investment banks across complex corporate, securities, and transactional matters. We combine deep industry experience with a streamlined, client-focused structure to deliver strategic, efficient, and globally informed legal solutions.

Learn More

Capital Markets

We have vast experience advising issuers and underwriters on a full range of equity and debt offerings.  We regularly work on IPOs with Nasdaq or NYSE listings, as well as post-IPO transactions including registered direct offerings (RDOs) and at-the-market offerings (ATMs).  We also advise companies looking to access financial markets for the first time on the OTC markets, as well as Regulation A, Regulation D and Regulation S transactions.

Corporate and M&A

Our Corporate and M&A team advises companies and financial advisors worldwide on a wide range of domestic and cross-border public and private transactions. Our experience includes negotiated and unsolicited acquisitions, auctions, minority investments, joint ventures, spin-offs, and corporate reorganizations. Our experienced team regularly structures, negotiates, and implements highly complex deals on behalf of our clients. We also advise on the incorporation and transformation of all forms of corporations and partnerships.

Capital Markets

We have vast experience advising issuers and underwriters on a full range of equity and debt offerings.  We regularly work on IPOs with Nasdaq or NYSE listings, as well as post-IPO transactions including registered direct offerings (RDOs) and at-the-market offerings (ATMs).  We also advise companies looking to access financial markets for the first time on the OTC markets, as well as Regulation A, Regulation D and Regulation S transactions.

Corporate and M&A

Our Corporate and M&A team advises companies and financial advisors worldwide on a wide range of domestic and cross-border public and private transactions. Our experience includes negotiated and unsolicited acquisitions, auctions, minority investments, joint ventures, spin-offs, and corporate reorganizations. Our experienced team regularly structures, negotiates, and implements highly complex deals on behalf of our clients. We also advise on the incorporation and transformation of all forms of corporations and partnerships.

Sustained Partner Involvement, Every Day and Every Deal

Many of our Partners previously worked at some of most prestigious big law firms in the world.  As a boutique firm, Crone is deliberately structured to emphasize depth and senior-level engagement by our Partners. Our highly experienced team ensures sustained Partner involvement, careful stewardship of each matter, and a level of attention that larger, more layered firms are often unable to provide.

Meet Our Team

Locations

Los Angeles

12121 Wilshire Blvd., Suite 810
Los Angeles, CA 90025
+1 (818) 930-5686

New York

420 Lexington Avenue, Suite 2446
New York, NY 10170
+1 (646) 861-7891

Beijing

St. Regis Residences, Suite 737
No. 21 Jianguomenwai Street
Chaoyang District
Beijing 1000020
+86 139 0290 0927

Locations

New York

420 Lexington Avenue, Suite 2446
New York, NY 10170
+1 (646) 861-7891

Los Angeles

12121 Wilshire Blvd., Suite 810
Los Angeles, CA 90025
+1(818) 930-5686

Bejing

St. Regis Residences, Suite 737
No. 21 Jianguomenwai Street
Chaoyang District
Beijing 1000020
+86 139 0290 0927

Company News
SMJ International Holdings Inc. Announced Closing of $10 Million Initial Public Offering (NYSE: SMJF)

SINGAPORE – (BUSINESSWIRE) – SMJ International Holdings Inc. (“SMJ” or the “Company”), a Singapore-based premium flooring specialist that distributes a wide range of premier flooring products under its proprietary “SMJ” brand across Asia markets, announced the closing its  initial public offering (the “Offering”) of an aggregate 2,500,000 Class A ordinary shares par value US$0.0002 per share at a price of US$4.00 per share to the public (the “Offering Price”), for a total of US$10,000,000 of gross proceeds to the Company, before deducting underwriting discounts and other offering expenses.

Read More →
Citius Oncology, Inc. Announces Closing of $9 Million Registered Direct Offering and Concurrent Private Placement (Nasdaq: CTOR)

CRANFORD, N.J., Sept. 10, 2025 /PRNewswire/ – Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, announced the closing of its previously announced registered direct offering and concurrent private placement of an aggregate of 5,142,858 shares of common stock and unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrant was $1.75. The warrants have an exercise price of $1.84 per share, will be exercisable six months from the date of issuance, and will expire on the five and one-half year anniversary from the date of issuance.

Read More →
Curanex Pharmaceuticals Inc. Announces Closing of $15 Million Initial Public Offering (Nasdaq: CURX)

Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the closing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering was conducted on a firm commitment basis. The Company’s shares of common stock began trading on the Nasdaq Capital Market on August 26, 2025 under the ticker symbol “CURX.”

Read More →